[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-pain":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,339,0,25,[9,43,62,102,133,156,178,206,233,254,274,294,317,341,364,393,418,448,478,503,524,550,568,592,615],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100643141","phase-2-a-chronic-pain-master-protocol-cpmp-a-study-of-ly4065967-in-participants-with-chronic-low-back-pain-100643141",false,"NCT07641504","A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Chronic Low Back Pain","Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY4065967 for the Treatment of Chronic Low Back Pain","BP07","Inclusion Criteria:\n\n* Have a history of low back pain for at least 3 months located between the 12th thoracic vertebra and the lower gluteal folds, with or without radiation\n* Have a body mass index at screening of ≤40 kilograms per meter squared (kg\u002Fm²).\n* Have stable glycemic control as indicated by a glycated hemoglobin (HbA1c) less than or equal to 10 at time of screening\n\nExclusion Criteria:\n\n* Are pregnant or breastfeeding\n* Have used a therapeutic injection to the spine in the 3 months prior to screening\n* Are using a spinal cord stimulator or dorsal root ganglion stimulator\n* Have ongoing complex regional pain syndrome or other concurrent medical conditions that could interfere with the evaluation of CLBP\n* Have a history of major spinal deformity, such as spondylolisthesis, spondylolysis, scoliosis, or spina bifida, that causes instability to the spine\n* Have an abnormal blood pressure (BP) systolic BP is greater than 140 millimeters mercury (\\>140 mm Hg) and diastolic BP\\>90 mm Hg at screening • Have history or current clinically significant cardiac disease, including arrhythmia, aortic aneurysm, heart failure, current electrolyte abnormalities, or any other conditions that could predispose to arrhythmia in the judgement of the investigator","ALL","18 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The main purpose of this study is to test the safety and efficacy of study drug for the treatment of chronic low back pain (CLBP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.",[28,29],"Chronic Pain","Low Back Pain","RECRUITING","2026-08-20",{"date":33,"type":34},"2026-08-21","ACTUAL",{"date":36,"type":34},"2026-08-12",{"date":38,"type":22},"2027-04",{"name":40,"class":41},"Eli Lilly and Company","INDUSTRY",37,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":61,"locationsCount":42},"100642998","phase-2-a-chronic-pain-master-protocol-cpmp-a-study-of-ly4065967-in-participants-with-osteoarthritis-pain-100642998","NCT07641517","A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain","Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY4065967 for the Treatment of Osteoarthritis","OA07","Inclusion Criteria:\n\n* Have presence of index knee pain for more than 12 weeks at screening\n* Have an x-ray supporting diagnosis of osteoarthritis according to the American College of Rheumatology with a Kellgren-Lawrence grade 2 to 4 radiographic classification of index knee\n* Have a body mass index ≤40 kilograms per meter squared (kg\u002Fm²) (inclusive)\n* Have stable glycemic control as indicated by a glycated hemoglobin (HbA1c) less than or equal to 10 at time of screening\n\nExclusion Criteria:\n\n* Are pregnant or breastfeeding\n* Have had a surgical procedure or therapeutic injection in the affected knee within 3 months prior to screening\n* Have presence of surgical hardware or other foreign body in the index knee\n* Have ongoing complex regional pain syndrome or other concurrent medical condition that could interfere with the evaluation of pain in the index knee.\n* Have had any joint replacement of the lower extremity, such as hip, knee or ankle, in the 6 months prior to screening\n* Have an abnormal blood pressure (BP) (systolic BP greater than 140 millimeters mercury (\\>140 mm Hg) and diastolic BP\\>90 mm Hg) at screening\n* Have history or current clinically significant cardiac disease, including arrhythmia, aortic aneurysm, heart failure, current electrolyte abnormalities, or any other conditions that could predispose to arrhythmia in the judgement of the investigator","40 Years",{"count":21,"type":22},[25],"The main purpose of this study is to test the safety and efficacy of study drug for the treatment of knee pain due to osteoarthritis (OA). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.",[56,28],"Osteoarthritis, Knee",{"date":33,"type":34},{"date":59,"type":34},"2026-06-25",{"date":38,"type":22},{"name":40,"class":41},{"id":63,"slug":64,"hasResults":12,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":18,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":74,"studyType":75,"phases":4,"briefSummary":76,"conditions":77,"keywords":81,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":4},"100652850","national-survey-of-chronic-occupational-pain-in-thai-anesthesia-providers-100652850","NCT07778381","National Survey of Chronic Occupational Pain in Thai Anesthesia Providers","Prevalence, Impacts, and Associated Factors of Chronic Occupational Pain Among Anesthesiologists and Nurses Anesthetists in Thailand: A National Survey","Inclusion Criteria:\n\n* Currently practicing as an anesthesiologist, anesthesia resident, or nurse anesthetist in a hospital in Thailand.\n* Aged between 25 and 60 years.\n* Have been working in their current clinical position and performing anesthesia-related tasks for at least 6 months.\n\nExclusion Criteria:\n\n* Currently on extended leave (e.g., long-term sick leave, maternity leave, or study leave) during the survey period.\n* Unwilling or unable to provide informed consent to participate in the study.",true,"25 Years","60 Years",{"count":73,"type":22},1800,"1 Day","OBSERVATIONAL","The purpose of this nationwide cross-sectional survey is to determine the prevalence, multidimensional impacts, and associated factors of chronic occupational pain among anesthesiologists and nurse anesthetists in Thailand. Due to the physically demanding nature of anesthesia practice-such as prolonged standing, awkward postures during airway management, and high-stress environments-work-related musculoskeletal disorders are highly prevalent but often underreported. This study aims to collect self-reported data via an anonymous online questionnaire to assess pain severity, specific anatomical locations, economic burdens (including absenteeism and presenteeism), and the overall impact on the health-related quality of life. Ultimately, the findings from this study will help establish a national evidence-based database to improve workplace safety, inform occupational health policies, and enhance the overall well-being of anesthesia providers in Thailand.",[28,78,79,80],"Musculoskeletal Pain","Occupational Pain","Occupational Diseases",[82,83,84,85,86,87,88,89,90,91],"Anesthesiologists","Nurse Anesthetists","Anesthesia Providers","Healthcare Personnel","Work-Related Musculoskeletal Disorders (WMSDs)","Occupational Health","Ergonomics","Quality of Life","Presenteeism","Absenteeism","NOT_YET_RECRUITING","2026-08-19",{"date":33,"type":34},{"date":96,"type":22},"2026-08-15",{"date":98,"type":22},"2027-01-01",{"name":100,"class":101},"Mahidol University","OTHER",{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":132},"100643683","prospective-case-series-evaluating-6-month-and-12-month-outcomes-after-cryoneurolysis-for-chronic-pain-100643683","NCT07639060","Prospective Case Series Evaluating 6-Month and 12-Month Outcomes After Cryoneurolysis for Chronic Pain","Inclusion Criteria:\n\n* Diagnosis of chronic pain (generally pain duration of at least 3-6 months) localized to an anatomical region appropriate for cryoneurolysis as determined by the treating physician.\n* Planned cryoneurolysis procedure as part of standard clinical care.\n* Ability to provide written informed consent.\n* Ability and willingness to complete baseline and follow-up questionnaires.\n\nExclusion Criteria:\n\n* Cryoneurolysis performed as part of a separate investigational trial in which data sharing is not permitted.\n* Active infection or other clinical contraindication to the procedure as determined by the treating clinician.\n* Life expectancy of less than 12 months in the judgment of the treating clinician.\n* Any condition that, in the investigator's opinion, would interfere with study participation or completion of follow-up, such as severe psychiatric instability or active substance use that precludes reliable follow-up",{"count":109,"type":22},80,"To prospectively describe patient-centered and health utilization outcomes through 12 months after cryoneurolysis performed as routine clinical care for chronic pain at Yale.",[28,112,113,114,115,116,117,118,119,120,121,122,123,124],"PERIPHERAL NEUROPATHY","Occipital Neuralgia","Chronic Hip Pain","Hip Osteoarthritis","Knee Osteoarthritis","Spasticity","Chronic Low Back Pain","Lumbar Spondylosis","Cervical Spondylosis","Shoulder Arthritis","Causalgia","Chronic Pain Syndrome","Chronic Neck Pain",{"date":33,"type":34},{"date":127,"type":34},"2026-06-20",{"date":129,"type":22},"2028-07",{"name":131,"class":101},"Yale University",1,{"id":134,"slug":135,"hasResults":12,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":150,"startDateStruct":151,"completionDateStruct":152,"leadSponsor":154,"locationsCount":132},"100632307","effect-of-rebound-pain-on-chronic-postsurgical-pain-after-total-knee-arthroplasty-100632307","NCT07511985","Effect of Rebound Pain on Chronic Postsurgical Pain After Total Knee Arthroplasty","Effect of Rebound Pain on Chronic Postsurgical Pain After Total Knee Arthroplasty: A Prospective Observational Study","Inclusion Criteria:\n\n* Age 18 years or older\n* ASA physical status I to III\n* Scheduled for unilateral elective total knee arthroplasty\n* Planned to undergo spinal anesthesia\n* Planned to receive a peripheral nerve block as part of routine multimodal analgesia\n* Able to provide informed consent and complete study assessments\n\nExclusion Criteria:\n\n* Chronic opioid use (60 mg oral morphine equivalent per day or more, or use for 3 months or longer)\n* Significant neuropathy or radiculopathy\n* Bilateral or two-stage total knee arthroplasty during the same hospitalization\n* Contralateral total knee arthroplasty within the previous 6 months\n* Severe cognitive impairment or major psychiatric disorder\n* Chronic analgesic dependence",{"count":141,"type":22},220,"This prospective observational study aims to evaluate whether rebound pain after peripheral nerve block is associated with the development of chronic postsurgical pain following elective total knee arthroplasty. Adult patients undergoing unilateral total knee arthroplasty under spinal anesthesia and receiving a peripheral nerve block as part of routine multimodal analgesia will be included. No additional intervention, drug administration, or biological sampling will be performed beyond standard clinical care.\n\nRebound pain will be assessed during the early postoperative period using pain diaries, numeric rating scale pain scores, and analgesic consumption records. Chronic postsurgical pain and related outcomes will be evaluated at postoperative 3 and 6 months using validated instruments assessing pain severity, neuropathic pain features, psychological status, functional outcomes, and health-related quality of life. The primary outcome is the presence of chronic postsurgical pain at 3 months after surgery. Secondary outcomes include chronic pain at 6 months, pain intensity, neuropathic pain characteristics, opioid consumption, rescue analgesic requirements, sleep disturbance, and quality-of-life measures. The study also aims to explore demographic and clinical factors associated with rebound pain and chronic postsurgical pain.",[144,28,145],"Acute Pain, Postoperative","Arthroplasty, Replacement, Knee",[147,148,149],"rebound pain","chronic postsurgical pain","total knee arthroplasty",{"date":31,"type":34},{"date":93,"type":34},{"date":153,"type":22},"2026-12-12",{"name":155,"class":101},"Konya City Hospital",{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":165,"briefSummary":167,"conditions":168,"keywords":169,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":171,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":175,"locationsCount":132},"100600191","prospective-assessment-of-integrative-therapies-for-neuromusculoskeletal-pain-pain-100600191","NCT07094282","Prospective Assessment of Integrative Therapies for Neuromusculoskeletal Pain (PAIN)","PAIN","\\*\\*Patients must be able to get care at Nellis Air Force Base (a military installation) in order to participate in this study\\*\\*\n\nInclusion Criteria:\n\n* Active Duty and DoD Beneficiaries (i.e. former military, spouse, dependent child) aged 18 or older referred to the Nellis Integrative Medicine Clinic chronic back or neck pain\n* Pain Chronicity Threshold (pain score ≥4\u002F10 documented in EMR or reported by patient at least 2 times in one year and at least 30 days apart).\n\nExclusion Criteria:\n\n* Enrolled in other pain management program (e.g. pain management, PT\n\n  \u002FOT)\n* Anticipated Change of station, deployment, retirement from military service, separation from active or reserve military service (includes national guard) or plan to discontinue enrollment at MOMMC in \\\u003C6 months\n* Planned surgery during the study period\n* Pregnancy\n* \\\u003C3 months post-partum\n* Hypermobility disorders such as Ehlers Danlos\n* Active cancer (cancer in remission is not an exclusion)\n* Implanted electrical devices that cannot be turned off (ie pacemaker); implanted stimulators or pumps that can be turned off are not exclusionary\n* Injury or surgery within the last 6 weeks\n* Dementia\n* Delirium\n* Inability to make medical decisions or understand treatment plan as decided upon by principle or associate investigators\n* Undergoing medical evaluation board\n* Currently in the process of establishing or appealing VA disability rating, or planning to do so within the study period",{"count":164,"type":22},125,[166],"NA","With vast numbers of active-duty members restricted from their specific duties or deemed unfit for deployment because of low back pain, both the mission of the Department of Defense and overall military workflow can be significantly impacted. More than restriction from duty or being barred from deployment, studies have shown musculoskeletal conditions were among the top reasons for medical disability retirement in the Army and Marine Corps (Niebuhr; Sikorski). Given the significant time, money, and resources invested in training these members, each day of inactivity or disability detrimentally affects the execution of the military's mission. Therefore, precise diagnosis and effective treatment modalities are paramount to foster healing and reduce recovery time.\n\nFrom an operational standpoint, the United States Department of Defense (DoD) is specifically interested in using tailored integrative medicine modalities to manage chronic conditions encountered in the military health system. Not just chronic pain, but polytrauma and the triad of conditions it encompasses; traumatic brain injury and post-traumatic stress disorder combined with chronic pain (Madsen, Kim, Bedard). The DoD's goal is also to decrease opioid prescribing and the addiction and altered state associated with opioids.\n\nAT the Nellis Integrative Medicine Clinic, physicians, a chiropractor, and nurses are engaged in the treatment of patients. All personnel are trained in the various modalities available in the clinics.\n\nA variety of modalities are utilized in the clinic. This prospective study will evaluate the effectiveness of the many modalities used in the Integrative Medicine Clinic (such as acupuncture, myofascial therapies, microcurrent therapies, LASER therapy, extracorporeal shockwave therapy, and pulsed electromagnetic therapies).\n\nMost patients receive treatments using multiple modalities. DoD goals align with our experiences in the Integrative Medicine Clinic at Mike O'Callaghan Military Medical Center. Many servicemembers and dependents in our clinic are trying to avoid surgery, or their pain medications - opioid or not - are no longer working. Additionally, many patients are trying to avoid Do Not Fly status caused by pharmacologic approaches. Patient experiences at our IMC also correlate with a study where 80% of people surveyed felt integrative medicine should be routinely offered at all MTFs (Ross). While our patients generally are not on opioids, we have anecdotally noted a reduction or cessation of opioids in several patients. The impacts of such a reduction in opioid usage for military readiness is clear (Madsen).",[28],[170],"integrative medicine",{"date":33,"type":34},{"date":173,"type":34},"2025-08-04",{"date":129,"type":22},{"name":176,"class":177},"David Moss","FED",{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":23,"phases":187,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":132},"100652950","burstdr-spinal-cord-stimulation-versus-sham-in-established-responders-100652950","NCT07779733","BurstDR Spinal Cord Stimulation Versus Sham in Established Responders","Passive Recharge Burst Spinal Cord Stimulation vs Sham Stimulation in Established Responders: A Randomized, Double-Blind Crossover Clinical Trial","Inclusion Criteria\n\nParticipants must meet all of the following:\n\n1. Be 18 years of age or older.\n2. Have an implanted spinal cord stimulation system that can deliver BurstDR stimulation.\n3. Have had a good and stable response to BurstDR therapy, defined as at least a 50% reduction in pain compared with pain before implantation or before starting BurstDR therapy, maintained for at least 3 months on stable stimulation settings.\n4. Have had no major change in pain medication for at least 4 weeks before entering the study.\n5. Be able to understand the study information and provide written informed consent.\n6. Be willing and able to complete the study's electronic diaries and follow the study procedures.\n\nExclusion Criteria\n\nParticipants cannot take part if any of the following apply:\n\n1. An active infection, wound problem, or other significant problem at the site of the implanted spinal cord stimulation system.\n2. A known or suspected problem with the implanted stimulation system that could affect treatment delivery or safety.\n3. A serious uncontrolled mental health condition, significant problems with memory or thinking, or another condition that could make it difficult to understand the study, provide informed consent, follow the study procedures, or provide reliable study information.\n4. Planned surgery, planned changes to spinal cord stimulation programming outside the study, or an expected change in pain medication during the study period.\n5. Pregnancy or breastfeeding.\n6. Inability to use the electronic diary system when no practical alternative or assistance can be provided.\n7. Any other medical or personal condition that, in the investigator's judgment, would make participation unsafe or inappropriate.",{"count":186,"type":22},28,[166],"This study aims to determine whether ongoing BurstDR spinal cord stimulation (SCS) provides pain relief beyond sham stimulation in patients with chronic pain who are established responders to BurstDR therapy.\n\nParticipants already implanted with an SCS system and experiencing stable clinical benefit from BurstDR will undergo both active stimulation and sham stimulation in a randomized, double-blind crossover design. Each participant will therefore serve as their own control.\n\nThe primary question is whether pain intensity is lower during active BurstDR stimulation compared with sham stimulation. The study will also evaluate treatment satisfaction, patient-reported changes in sleep, mood, daily activity and social activity, the effectiveness of blinding, and short-term safety and tolerability.",[28],[191,192,193,194,195,196,197],"Spinal Cord Stimulation","Passive Recharge Burst Spinal Cord Stimulation","Burst Stimulation","Neuromodulation","Sham Stimulation","Paresthesia-Free Stimulation","Established Responders","2026-08-18",{"date":33,"type":34},{"date":201,"type":22},"2026-09-30",{"date":203,"type":22},"2027-03-31",{"name":205,"class":101},"Umeå University",{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":23,"phases":215,"briefSummary":216,"conditions":217,"keywords":222,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":226,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":132},"100649992","feasibility-and-acceptability-of-empowered-relief-for-american-indians-with-pain-during-and-after-cancer-treatment-100649992","NCT07742449","Feasibility and Acceptability of Empowered Relief for American Indians With Pain During and After Cancer Treatment","ejames3","Inclusion Criteria:\n\n* Identifies as American Indian\n* Has history of a cancer diagnosis\n* Is currently undergoing or has completed active cancer treatment\n* Experiences body pain most or every day\n* Pain duration at least 3 months\n* English fluency\n\nExclusion Criteria:\n\n* Significant psychological and cognitive impairment that limits one's ability to complete study tasks (completion of online survey, attending the Zoom-based ER class)\n* Life-threatening acute illness (e.g., infection, heart attack, injury)\n* No access to a computer, a smartphone, or a tablet",{"count":214,"type":22},70,[166],"This project will evaluate the feasibility and acceptability of Empowered Relief (ER) among American Indian adults who are currently receiving or have completed active cancer treatments at Stephenson Cancer Center (SCC). ER is a single-session, Zoom-based, 2-hour, skills-based pain management class delivered by certified instructors. Participants learn three core pain relief skills, develop a personalized plan, and receive access to a free binaural audio app for daily practice. ER has demonstrated moderate efficacy in individuals with chronic non-cancer pain, reducing pain intensity, pain interference, pain-related distress (pain catastrophizing), sleep disturbance, and anxiety at 3 and 6 months post-treatment. Because of its brief, didactic nature and Zoom delivery, ER can accommodate large class sizes and may address accessibility disparities among underserved cancer populations. While ER is being studied across various non-cancer populations and has been adopted as standard of care in leading healthcare institutions in the U.S. and abroad, it has not been tested in American Indians with cancer.",[218,219,220,28,221],"Cancer","Pain","Pain Management","American Indian or Alaska Native",[218,223,219,28,224,225],"Cancer Survivor","Native American","American Indian",{"date":31,"type":34},{"date":228,"type":22},"2026-08-01",{"date":230,"type":22},"2027-12",{"name":232,"class":101},"University of Oklahoma",{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":18,"minAge":240,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":23,"phases":243,"briefSummary":244,"conditions":245,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":247,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":132},"100624052","video-intervention-for-older-adults-with-chronic-pain-100624052","NCT07404618","Video Intervention for Older Adults With Chronic Pain","Development and Preliminary Testing of a Peer Narrative Video Intervention for Older Adults With Chronic Pain","Inclusion Criteria:\n\n1. Chronic MSK pain. Consistent with existing guidance, the experience of pain must be present most days of the week over the past 3 months, of at least moderate intensity.\n2. Pain interferes with everyday activities.\n3. Age 55 or older.\n4. Proficiency in English sufficient to engage in informed consent and understand assessments and materials.\n5. Reliable internet access.\n\nExclusion Criteria:\n\n1. Currently receiving acceptance\u002Fmindfulness or similar psychotherapy for chronic pain management.\n2. Current severe substance use problems.\n3. Cognitive impairment that would interfere with a person's capacity to complete the study.","55 Years",{"count":242,"type":22},100,[166],"Chronic musculoskeletal (MSK) pain, which includes spinal pain, osteoarthritis, and fibromyalgia, is a common and costly problem for older adults and is associated with decreased quality of life. In this project, investigators propose to create Reclaim Your Day (RYD), which will consist of 6, 30-min weekly video episodes highlighting patients' inspiring and illustrative experiences living with chronic pain in order to teach current patients with chronic MSK pain how to apply ACT's evidence-based strategies. INvestigators will conduct a pilot RCT (n=100) of older adults with chronic MSK pain. All participants will receive an introductory pain education video. Participants will be randomized to receive either RYD or a comparison intervention (health education videos). Investigators will examine RYD feasibility and acceptability as well as changes over time in outcomes (pain interference, depression, quality of life) and putative mediators.",[28,78,246],"Older Adults With Chronic Pain",{"date":93,"type":34},{"date":249,"type":34},"2026-05-01",{"date":251,"type":22},"2027-12-31",{"name":253,"class":101},"Butler Hospital",{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":23,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":266,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":273},"100490113","phase-2-from-nerve-to-brain-toward-a-mechanistic-understanding-of-spinal-cord-stimulation-in-human-subjects-100490113","NCT05661903","From Nerve to Brain: Toward a Mechanistic Understanding of Spinal Cord Stimulation in Human Subjects","Inclusion Criteria:\n\n* Aged 18 to 80\n* Capable of providing informed consent and following trial procedures, including capacity to complete self-reported measures of pain, function, and other outcomes\n* Stably implanted spinal cord or dorsal root ganglion stimulator\n* Device is to treat back\u002Fradicular lower extremity pain or neck\u002Farm pain\n* Device with a paresthesia-free setting\n\nExclusion Criteria:\n\n* Patients who are not on a stable dose of opioids or are on a stable dose greater than 100 MME\u002Fday per day within the two months prior to enrollment, or those who are unwilling to maintain a stable dose of opioids throughout the duration of the study\n* The investigator concludes that the participant is unable to differentiate back or neck\u002Farm pain from other pains\n* Systemic or psychiatric illness that in the opinion of the site investigator would interfere with the individual's ability to participate in the trial\n* Other factor that in the opinion of the site investigator would interfere with the individual's ability to participate in the trial or tolerate the study procedures\n\nDropout Criteria for Optional Imaging\n\n* Stimulation device is not 3 Tesla magnetic resonance imaging compliant\n* Contraindications to magnetic resonance imaging and\u002For positron emission tomography scanning (including presence of a cardiac pacemaker or pacemaker wires, vascular clips in the head or previous neurosurgery, prosthetic heart valves, claustrophobia)\n* Pregnant or breastfeeding\n* Participants with a low affinity binder phenotype based off testing for the Ala147Thr polymorphism.\n* Current or recent use of benzodiazepines (except for alprazolam, clonazepam, and lorazepam). Recent use will be defined based off the benzodiazepines half-life, such that patients who stopped taking the medication at least five half-lives ago will be considered eligible for scanning.\n* Subjects who have exceeded (or would exceed if they were to participate) the yearly amount of allowable radiation, as defined by the Radiation Safety Committee\n* In the opinion of the investigators, unable to safely participate in this study and\u002For provide reliable data (e.g., unlikely to remain still during the imaging procedures).","80 Years",{"count":262,"type":22},180,[25],"This is a multicenter prospective study of patients who currently have stably implanted spinal cord simulators. Patients will be randomly assigned to turn on or off their spinal cord stimulators for two week intervals up to six weeks after enrollment, and on the final day of study participation, for one hour intervals, in a multi-crossover design. In a subset of patients we will also perform combined positron emission tomography\u002Fmagnetic resonance imaging at baseline, week 2 and week 4.",[28],{"date":31,"type":34},{"date":268,"type":34},"2023-06-08",{"date":270,"type":22},"2027-08-31",{"name":272,"class":101},"Massachusetts General Hospital",3,{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":23,"phases":283,"briefSummary":284,"conditions":285,"keywords":286,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":289,"completionDateStruct":290,"leadSponsor":292,"locationsCount":132},"100652579","veterans-affairs-augusta-100652579","NCT07776600","VETERANS AFFAIRS AUGUSTA","Evaluating the Effectiveness of a Text\u002FTelephone-Delivered Chatbot Intervention for Chronic Pain Management Among High- Utilizing Veterans","Inclusion Criteria:Participants must meet all of the following eligibility criteria to be enrolled in the study:\n\n* Be a Veteran receiving care at the VA Augusta Health Care System Pain Medicine Service.\n* Be aged 18 or older.\n* Have a documented diagnosis of chronic pain (defined as pain persisting longer than 3 months).\n* Be classified as a high utilizer of VA in-person outpatient services, defined as having 4 or more in-person primary care, behavioral health, or pain-related visits within the past 6 months.\n* Be English-speaking.\n* Have access to a telephone (landline or cell phone).\n* Have capacity to provide informed consent.\n\nExclusion Criteria:\n\n* Individuals will be excluded from the study if they:\n\n  * Have moderate to severe cognitive impairment that would interfere with the ability to engage with a text\u002Ftelephone-based chatbot (as determined through medical record review or clinical judgment).\n  * Have active psychosis or acute psychiatric instability (e.g., recent psychiatric hospitalization in the past month) that would impair study participation.\n  * Are enrolled in another conflicting behavioral intervention study.\n  * Are non-English speaking, due to the current availability of the chatbot only in English.",{"count":282,"type":22},200,[166],"Chronic pain is a prevalent and debilitating condition among Veterans, often accompanied by depression, anxiety, sleep disturbances, and social isolation. Despite the availability of behavioral interventions many Veterans-particularly those with high in-person healthcare utilization-face barriers to accessing non-pharmacological pain management strategies. These barriers include limited clinician availability, geographic constraints, and digital exclusion among older or underserved populations.\n\nThis study aims to evaluate the feasibility, acceptability, and preliminary impact of My AI Companion, an automated, text\u002Ftelephone-delivered chatbot designed to support chronic pain self-management among high-utilizing Veterans. The intervention offers a low-barrier approach to promoting symptom tracking, patient activation, and engagement in coping strategies-without requiring Internet access or clinician time.",[28],[219],"2026-08-17",{"date":31,"type":34},{"date":228,"type":34},{"date":291,"type":22},"2028-08",{"name":293,"class":41},"Companion IQ, Inc",{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":23,"phases":303,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":310,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":132},"100643267","empowered-relief-for-caregivers-100643267","NCT07636980","Empowered Relief for Caregivers","Empowered Relief for Caregivers (ER-CY): A Co-Designed Brief Intervention to Support Families of Youth With Chronic Pain","ER-CY","Inclusion Criteria:\n\n* Caregiver of a youth with a chronic pain diagnosis (\\>3 months in duration)\n* English speaking\n\nExclusion Criteria:\n\n* Significant psychosocial complexity based on clinical team assessment (e.g., severe depression\u002Fanxiety, unable to tolerate a group setting)",{"count":109,"type":22},[166],"This study is testing a new program called Empowered Relief for Caregivers (ER-CY), designed to support caregivers of children and teens who live with chronic pain. ER-CY is a single two-hour class delivered online. It teaches skills for managing the stress of caring for a child in pain and for responding to a child's pain in helpful ways.\n\nUp to 80 caregivers of youth with chronic pain will take part in one ER-CY class and then complete surveys and a short interview over the following three months. The researchers want to learn two things: whether caregivers are willing and able to take part and find the program helpful and satisfying, and whether the program lowers caregiver distress and improves their child's day-to-day functioning. What is learned will help guide future programs and care for youth with chronic pain and their families.",[28,78,306,307,308,309],"Fibromyalgia","Neuropathic Pain","Complex Regional Pain Syndromes (CRPS)","Abdominal Pain (AP)",{"date":31,"type":34},{"date":312,"type":22},"2026-10",{"date":314,"type":22},"2028-09",{"name":316,"class":101},"Stanford University",{"id":318,"slug":319,"hasResults":12,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":4,"eligibilityCriteria":323,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":324,"targetDuration":74,"studyType":75,"phases":4,"briefSummary":326,"conditions":327,"keywords":329,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":336,"completionDateStruct":337,"leadSponsor":339,"locationsCount":132},"100651861","pain-phenotypes-in-individuals-with-multiple-sclerosis-100651861","NCT07766213","Pain Phenotypes in Individuals With Multiple Sclerosis","Pain Phenotyping in Multiple Sclerosis Based on IASP Criteria","Inclusion Criteria:\n\n* Age 18 years or older\n* Definite diagnosis of multiple sclerosis according to the McDonald criteria\n* No MS relapse or high-dose steroid treatment within the previous 3 months\n* Pain intensity ≥2 on the Numeric Rating Scale in at least one body region for at least 3 months\n* Ability to read, understand, and communicate in Turkish\n\nExclusion Criteria:\n\n* Pregnancy\n* Severe psychiatric disorder and\u002For severe cognitive impairment confirmed by a neurologist or neuropsychiatrist\n* Presence of a serious pathology or disease that may compromise the assessment process or affect clinical decision-making, including metastasis, cancer, untreated or unhealed fractures, neurological disorders other than multiple sclerosis, or a history of diabetes",{"count":325,"type":22},60,"This observational cross-sectional study aims to determine chronic pain phenotypes in individuals with multiple sclerosis (MS) and to investigate the clinical characteristics associated with different pain phenotypes. Participants with MS and chronic pain will undergo a comprehensive clinical assessment to identify nociceptive, neuropathic, nociplastic, and mixed pain phenotypes. The assessment will include clinical history, pain characteristics and distribution, quantitative sensory testing, pain intensity, disease severity, fatigue, health-related quality of life, and pain catastrophizing. The clinical characteristics of participants with different pain phenotypes will subsequently be compared.",[328,28],"Multiple Sclerosis",[330,331,332,333],"CHRONIC PAIN","NEUROPATHIC PAIN","NOCIPLASTIC PAIN","MULTIPLE SCLEROSIS","2026-08-14",{"date":198,"type":34},{"date":96,"type":22},{"date":338,"type":22},"2027-09-15",{"name":340,"class":101},"Kutahya Health Sciences University",{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":260,"enrollmentInfo":347,"targetDuration":4,"studyType":23,"phases":349,"briefSummary":350,"conditions":351,"keywords":353,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":357,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":132},"100378335","noninvasive-brain-stimulation-for-treating-carpal-tunnel-syndrome-100378335","NCT04206215","Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome","Inclusion Criteria:\n\n1. Able to provide informed consent to participate in the study\n2. Subjects between 18 to 80 years old\n3. Having symptomatic CTS spreading within or beyond the median nerve distribution (demonstrating 'extra-median spread'), involving at least 1 wrist, with chronic pain as defined by International Association for the Study of Pain (existing pain for at least 6 months and having pain on at least half the days in the past 6 months with an average of at least a 3 on a 0-10 VAS scale).\n4. Pain resistant to first line therapies of chronic pain (pain still present at lower levels most of the time following therapy)\n5. Must have the ability to feel pain as self-reported.\n\nExclusion Criteria:\n\n1. Subject is pregnant\n2. Contraindications to tDCS+TUS:\n\n   1. intracranial metal implant\n   2. implanted brain medical devices\n3. History of alcohol or drug abuse within the past 6 months as self-reported\n4. Use of carbamazepine within the past 6 months as self-reported\n5. Suffering from major depression (with a PHQ-9 score of ≥20)\n6. History of neurological disorders involving stroke, brain tumors, or epilepsy with residual neurological symptoms as self-reported (note patients will also be evaluated via EEG at baseline about 1 week prior to stimulation and any patient showing abnormal EEG activity will be removed))\n7. History of unexplained fainting spells as self-reported\n8. History of head injury resulting in more than a momentary loss of consciousness as self-reported and with current neurological deficits\n9. History of intracranial neurosurgery as self-reported",{"count":348,"type":22},95,[166],"The purpose of this study is to assess the effects of tDCS in combination with TUS for the treatment of pain in subjects with Carpal Tunnel Syndrome. The investigators hypothesize that there will be a decrease in pain levels with active stimulation, when compared to sham stimulation.",[28,352],"Carpal Tunnel Syndrome",[354,355,356],"transcranial Direct Current Stimulation","Transcranial Ultrasound","Noninvasive brain stimulation",{"date":198,"type":34},{"date":359,"type":34},"2021-04-16",{"date":361,"type":22},"2027-12-28",{"name":363,"class":101},"Spaulding Rehabilitation Hospital",{"id":365,"slug":366,"hasResults":12,"nctId":367,"briefTitle":368,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":371,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":372,"conditions":373,"keywords":375,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":386,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":132},"100652215","integrative-ai-based-multiomic-and-neurophysiological-profiling-of-chronic-pain-in-rheumatoid-arthritis-100652215","NCT07769619","Integrative AI-Based Multiomic and Neurophysiological Profiling of Chronic Pain in Rheumatoid Arthritis","RA-PAIN-AI","Inclusion Criteria - Study Group (Active RA)\n\n* Age ≥18 years.\n* Confirmed diagnosis of rheumatoid arthritis according to applicable classification criteria.\n* Active phase of the disease requiring initiation of biological therapy.\n* Qualification for treatment under the national drug program B.33: \"Treatment of rheumatoid arthritis and juvenile idiopathic arthritis with aggressive course (ICD-10: M05, M06, M08)\".\n* Ability to provide written informed consent.\n* Willingness to participate in clinical assessments, EEG, biological sample collection, and questionnaire-based evaluation.\n\nExclusion Criteria - Study Group\n\n* Contraindications to biological therapy as defined by the Polish Society of Rheumatology recommendations and the National Health Fund (NFZ) requirements under the B.33 drug program.\n* Inability to provide informed consent.\n* Any condition that, in the opinion of the investigator, may interfere with study participation or data interpretation.\n\nInclusion Criteria - Control Group (RA in Remission)\n\n* Age ≥18 years\n* Confirmed diagnosis of rheumatoid arthritis.\n* Ongoing biological therapy with sustained remission for at least 1.5 years and good tolerance of the treatment.\n* No current chronic pain reported in the clinical interview.\n* Ability to provide written informed consent.\n* Willingness to participate in study procedures, including biological sampling, EEG and questionnaire assessments.",{"count":242,"type":22},"Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease in which pain remains the most prominent and burdensome symptom from the patient's perspective. Although the introduction of biological and targeted synthetic disease-modifying antirheumatic drugs (bDMARDs and tsDMARDs) has significantly improved the control of inflammatory activity, an estimated 20-30% of patients continues to experience persistent moderate-to-severe pain despite achieving clinical remission. This discordance between objective inflammatory markers and subjective pain perception reflects an important unmet clinical need and suggests that chronic pain in RA may become partially or fully independent of peripheral inflammation, driven instead by central sensitization and nociplastic mechanisms. The RA-PAIN-AI study is a prospective, observational, case-control study integrating clinical assessment, patient-reported outcome measures, neurophysiological evaluation, and multiomic profiling, analyzed using artificial intelligence (AI)-based methods. Two groups of adult patients with RA are enrolled: a study group of patients with active disease qualifying for biological therapy under the Polish national drug program B.33, and a control group of patients in sustained clinical remission (at least 1.5 years) under biological therapy, without clinically significant chronic pain. All participants undergo clinical assessment, standardized questionnaires, peripheral blood collection at the baseline (Visit 1) and follow-up (Visit 2) visits. Electroencephalography (EEG) is offered as an optional procedure, at the discretion of the investigator. Biological samples are analyzed using advanced multiomic technologies, including whole genome sequencing (genomics), mRNA expression profiling (transcriptomics), and measurement of circulating proteins (secretomics). All clinical, biological, and neurophysiological data are then integrated using AI methods, including dimensionality reduction, clustering, and supervised machine learning, to identify distinct pain-related patient subtypes (endotypes). The primary objective of the study is to identify and characterize clinical, neurophysiological, and multiomic signatures associated with chronic pain in RA. Expected outcomes include identification of biomarkers predictive of chronic pain persistence despite effective anti-inflammatory treatment, improved differentiation between inflammation-driven pain and pain mediated by central nervous system changes, and support for the development of more personalized, mechanism-based treatment strategies in rheumatology. The study is non-interventional: no experimental therapeutic interventions are administered, and all participants continue to receive standard clinical care. All biological analyses are performed ex vivo.",[374,28],"Rheumatoid Arthritis (RA",[376,377,378,379,380,381,382,383,384,385],"multiomics","pain endotypes","precision medicine","biomarkers","artificial intelligence","electroencephalography","nociplastic pain","secretomics","transcriptomics","ACPA",{"date":198,"type":34},{"date":388,"type":34},"2026-06-01",{"date":390,"type":22},"2029-06-06",{"name":392,"class":101},"4th Military Clinical Hospital with Polyclinic, Poland",{"id":394,"slug":395,"hasResults":12,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":4,"eligibilityCriteria":399,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":400,"targetDuration":4,"studyType":23,"phases":402,"briefSummary":404,"conditions":405,"keywords":407,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":411,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":4},"100652081","early-phase-1-s1r-imaging-based-cryoneurolysis-in-chronic-pain-100652081","NCT07768501","S1R Imaging-Based Cryoneurolysis in Chronic Pain","Molecular Imaging-Based Cryoneurolysis: Targeting Upregulated Sigma-1 Receptor Positive Nerves in Chronic Pain","Inclusion Criteria:\n\n1. Chronic nociceptive, neuropathic, or mixed pain for ≥2 months\n2. Pain originating from a region amenable to cryoneurolysis (celiac plexus, intercostal nerves, pudendal nerve, peripheral nerve block\n3. Chronic pain ≥2 months\n4. Pain score ≥4\u002F10\n5. Pain location amenable to cryoneurolysis\n6. Willing and able to provide consent.\n\nExclusion Criteria:\n\n1. Pregnancy or nursing.\n2. Non-English speaking individuals\n3. Contraindication to MRI scanning which includes, but is not limited to, incompatible metal or hardware including pacemakers, cochlear implants, and bullets near a critical organ.\n4. Weight \\>350 pounds or a large body habitus, which the MR scanner cannot accommodate.\n5. Claustrophobia or feeling that he or she will be unable to lie still in the scanner for a period of 2 hours or fit in the PET\u002FMR scanner due to body size.",{"count":401,"type":22},6,[403],"EARLY_PHASE1","The goal of this clinical trial is to determine whether a sigma-1 receptor PET\u002FMRI scan can help identify the specific nerves responsible for chronic pain.\n\nResearchers will use an investigational imaging agent called \\[18F\\]FTC-146 to look for signs of pain generating nerve irritation or injury that may not be visible on convention imaging tests.\n\nParticipants whose pain-generating nerve can be identified may undergo a diagnostic nerve block and, if successful, a standard clinical procedure called cryoneurolysis will be used to temporarily interrupt pain signals.",[28,406],"Mixed Pain (Nociceptive and Neuropathic)",[408,409,410],"chronic pain","PET\u002FMRI","cryoneurolysis",{"date":287,"type":34},{"date":413,"type":22},"2026-09",{"date":415,"type":22},"2030-09",{"name":417,"class":101},"Davidzon, Guido, M.D.",{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":422,"acronym":423,"eligibilityCriteria":424,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":425,"targetDuration":4,"studyType":23,"phases":427,"briefSummary":428,"conditions":429,"keywords":430,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":440,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":447},"100604465","pain-management-teams-using-whole-health-to-optimize-function-and-safety-in-veterans-the-teamwork-trial-100604465","NCT07149870","Pain Management Teams Using Whole Health to Optimize Function and Safety in Veterans: The TEAMWORK Trial","TEAMWORK","Inclusion Criteria:\n\n1. High-impact chronic pain (defined using the Graded Chronic Pain Scale - Revised).\n2. Active prescription for long-term opioid therapy (LTOT; including full agonist and buprenorphine) (\\>90 days continuous prescription).\n3. Exhibit evidence of at least ONE opioid safety concern (\\*indicators of opioid safety concerns described below).\n\n   * Opioid safety concerns for inclusion purposes include:\n\n     1. moderate-to-high dose opioid prescription (morphine equivalent daily dose \\>60mg)\n     2. comorbid conditions that increase the risk of full-agonist opioids including chronic pulmonary disease (e.g., emphysema, chronic bronchitis, asthma, or other breathing problems), sleep apnea, chronic kidney disease, chronic hepatitis or cirrhosis\n     3. active high-risk co-prescriptions, including long-term benzodiazepine prescription, gabapentin or pregabalin, nonbenzodiazepine hypnotic agents or sedative hypnotics, or skeletal muscle relaxants\n     4. a positive TAPS or AUDIT-C score\n     5. reported score of \\>8 as measured by the Prescribed Opioids Difficulties Scale (PODS).\n\nExclusion Criteria:\n\n1. Moderate to severe cognitive impairment as measured by the Blessed Orientation Memory Concentration (BOMC) screening tool.\n2. Inability to read or understand English.\n3. Severely impaired hearing or speech that would preclude participation in telephone interviews or appointments with the Whole Health Coach.\n4. Terminal illness\u002Fdisease with a prognosis of \\\u003C12 months.\n5. Planned move\u002Frelocation outside of the treatment areas of the participating enrolling study sites.\n6. Participants actively working with a Whole Health Coach or who have worked with a Whole Health Coach in the 6-months prior to enrollment.\n7. Major surgical procedure planned during the study treatment or follow-up period.\n8. a recent suicide attempt, defined as documented and\u002For reported suicide attempt within 90 days of the screening date.",{"count":426,"type":22},432,[166],"The focus of this study is to determine whether adding Whole Health Coaching (WHC) improves pain care among adults with chronic pain and who are currently working with a pain management team (PMT) at the VA.",[28],[431,432,219,28,433,220,434,435,436,437,438,439],"Opioid Use","Opioid Safety","Long-term Opioid Therapy","Opioid","Whole Health","Coaching","Whole Health Coaching","Pain, Chronic","Buprenorphine",{"date":287,"type":34},{"date":442,"type":34},"2025-11-20",{"date":444,"type":22},"2029-10-01",{"name":446,"class":177},"VA Office of Research and Development",5,{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":454,"eligibilityCriteria":455,"healthyVolunteers":69,"sex":456,"minAge":457,"maxAge":260,"enrollmentInfo":458,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":460,"conditions":461,"keywords":465,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":471,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":475,"locationsCount":132},"100363639","evaluation-of-central-sensitization-fear-avoidance-and-pain-pressure-threshold-with-chronic-pain-after-hysterectomy-100363639","NCT04014829","Evaluation of Central Sensitization, Fear-Avoidance, and Pain-Pressure Threshold With Chronic Pain After Hysterectomy","Evaluation of Central Sensitization, Fear-Avoidance, and Pain-Pressure Threshold With Chronic Pain in Post-Hysterectomy Patients: A Collaborative Cohort Study (EPOCH - Enhancing Post-operative Outcomes in Chronic Pain After Hysterectomy)","EPOCH","Inclusion Criteria:\n\n* Age 21 to 80 years old\n* American Society of Anesthesiologists Physical Scale (ASA) I to III\n* Benign gynaecological indications for hysterectomy\n* Elective abdominal or laparoscopic hysterectomy\n\nExclusion Criteria:\n\n* Vaginal hysterectomy\n* Uterine prolapse, endometriosis, malignant disease, or pelvic pain as main indication for surgery\n* History of drug dependence or recreational drug use\n* History of chronic pain syndrome\n* Current chronic daily treatment with corticosteroids, excluding inhaled steroids\n* Allergy to study drugs\n* Major heart surgery\n* Heart transplant\n* Pacemaker inserted\n* Baseline non-sinus cardiac rhythm","FEMALE","21 Years",{"count":459,"type":22},436,"Phase 1 (started in July 2019):\n\nCentral Sensitization Inventory (CSI), Fear-Avoidance Components Scale (FACS), pain-pressure threshold are factors associated with chronic post-hysterectomy pain (CPHP), but a complete understanding on the development of CPHP is lacking. The study aims to identify clinically-relevant factors for CPHP that can be reliably assessed preoperatively.\n\n===\n\nPhase 2 (anticipated start May 2022):\n\nIn addition to above factors, the association between heart rate variability (HRV) parameters, anxiety level, anticipated pain, and anticipated analgesia requirement with significant postoperative pain and CPHP will be investigated.",[462,28,463,464],"Hysterectomy","Central Sensitisation","Anxiety Depression",[462,28,466,467,468,469,470],"Fear-Avoidance","Central Sensitization","Pain-Pressure Threshold","Mechanical Temporal Summation","Heart rate variability",{"date":334,"type":34},{"date":473,"type":34},"2019-07-23",{"date":230,"type":22},{"name":476,"class":477},"KK Women's and Children's Hospital","OTHER_GOV",{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":456,"minAge":19,"maxAge":4,"enrollmentInfo":486,"targetDuration":4,"studyType":23,"phases":488,"briefSummary":489,"conditions":490,"keywords":493,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":501,"locationsCount":4},"100651837","perioperative-yoga-therapy-and-endometriosis-surgery-100651837","NCT07765680","Perioperative Yoga Therapy and Endometriosis Surgery","The Effectiveness of Yoga Therapy on Chronic Pain, Endometriosis Symptoms and Quality of Life Following Surgery for Endometriosis","YOGENDOCHIR","* Adult woman (18 years or older) covered by a social health insurance scheme.\n* Surgery for endometriosis is indicated.\n* No assisted reproductive technology (ART) protocol planned within 6 months after surgery.\n* No chronic pain attributable to another disease or condition.\n* No yoga practice outside the study during participation.",{"count":487,"type":22},188,[166],"YOGENDOCHIR is a multicentre, prospective, randomised, controlled, parallel-group study involving 188 adult women scheduled to undergo surgery for endometriosis.\n\nThe study compares standard surgical management alone with the same management combined with a structured perioperative yoga therapy programme comprising 32 guided sessions (16 before and 16 after surgery), supplemented by a secure digital platform supporting independent practice and adherence monitoring.\n\nThe primary objective is to assess the effect of yoga therapy on endometriosis-related pain, as measured by the pain subscale of the Endometriosis Health Profile-30 (EHP-30). Participants are assessed before surgery and at 3, 6, and 12 months after the procedure.\n\nSecondary outcomes include quality of life, pain characteristics, fatigue, sleep, anxiety and depressive symptoms, sexual health, kinesiophobia, activities of daily living, medication use, healthcare utilisation, absenteeism, adherence, satisfaction, and the participants' ability to use the platform independently.",[491,28,492],"Endometriosis","Impairment of Quality of Life",[491,408,494,495],"yogatherapy","surgery","2026-08-10",{"date":334,"type":34},{"date":499,"type":22},"2026-10-01",{"date":444,"type":22},{"name":502,"class":101},"University Hospital, Lille",{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":510,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":512,"conditions":513,"keywords":514,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":518,"startDateStruct":519,"completionDateStruct":520,"leadSponsor":522,"locationsCount":132},"100646169","evaluation-of-alexithymia-in-chronic-pain-patients-with-spinal-cord-stimulation-100646169","NCT07696286","Evaluation of Alexithymia in Chronic Pain Patients With Spinal Cord Stimulation","The Relationship of Alexithymia With Pain and Quality of Life Scales in Chronic Pain Patients Who Underwent Spinal Cord Stimulation: A Cross-Sectional Observational Study","Inclusion Criteria:\n\n* \\- Being 18 years of age or older\n* Having undergone permanent spinal cord stimulation (SCS) implantation due to clinical indications\n* Providing written informed consent for study participation\n* Being literate\n* Having the cognitive capacity to complete the psychometric scales\n* No active, severe psychiatric disorders requiring immediate treatment (e.g., schizophrenia, bipolar affective disorder, severe psychotic disorders)\n\nExclusion Criteria:\n\n* Cognitive impairment or communication barriers that compromise the capacity to provide informed consent\n* Presence of active psychotic disorders or manic episodes\n* Suspected self-harm or suicide risk during the clinical interview\n* Presence of specific secondary causes that could explain the pain (e.g., active malignancy, active infection, acute fracture)",{"count":511,"type":22},20,"The purpose of this study is to investigate the relationship between alexithymia levels and clinical parameters, including pain intensity and quality of life, in chronic pain patients treated with spinal cord stimulation (SCS). Chronic neuropathic pain can lead to psychological distress and decreased quality of life. While SCS is an effective neuromodulation therapy for managing refractory pain, patient outcomes vary significantly, suggesting that biomedically similar patients experience different levels of relief due to psychosocial factors.\n\nAlexithymia, characterized by difficulties in identifying and describing emotions, may significantly influence the individual pain experience and treatment outcomes. In this cross-sectional observational study, patients who underwent SCS implantation for clinical indications will be evaluated. Clinical data regarding pain history will be collected retrospectively from patient files, while psychosocial profiles will be assessed at a single time point using validated psychometric questionnaires. The study aims to contribute to a better understanding of psychosocial variables in neuromodulation outcomes, potentially aiding in improved patient selection and expectation management.",[28],[330,191,515,89,516,517,194],"Alexithymia","Childhood Trauma","Anxiety and Depression",{"date":36,"type":34},{"date":388,"type":34},{"date":521,"type":22},"2027-06-01",{"name":523,"class":101},"Marmara University",{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":530,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":532,"targetDuration":4,"studyType":23,"phases":533,"briefSummary":534,"conditions":535,"keywords":540,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":547,"locationsCount":549},"100607611","managing-pain-using-optimized-sequences-by-adjusting-parameters-with-independent-current-control-100607611","NCT07190807","Managing Pain Using Optimized Sequences by Adjusting Parameters With Independent Current Control","Managing Pain Using Optimized Sequences by Adjusting Parameters With Independent Current Control (MOSAIC Study)","MOSAIC","Key Inclusion Criteria:\n\n* Persistent spinal pain syndrome (PSPS) Type I (or non-surgical refractory back pain), or PSPS Type II (Failed Back Surgery Syndrome, FBSS) diagnosis.\n* Diagnosed with chronic pain of the trunk and\u002For limbs for at least 6 months.\n* 18 years of age or older when written informed consent is obtained\n* Able to independently read and complete all questionnaires and assessments provided in English.\n* Signed a valid, IRB or EC approved informed consent form (ICF) provided in English.\n\nKey Exclusion Criteria:\n\n* Any pain-related diagnosis, medical or psychological condition that, in the Investigator's judgment might confound reporting of study outcomes (e.g., vascular or neurogenic claudication, osteoarthritis, plantar fasciitis, pelvic pain, anginal pain, chronic migraine, acute herniated disc, malignancy, untreated major depression, injury claim).\n* Significant cognitive impairment at Screening and Baseline visit that, in the opinion of the Investigator, would reasonably be expected to impair the study candidate's ability to participate in the study\n* A female who is pregnant, lactating, or is of childbearing potential and planning to get pregnant during the study or not using adequate contraception.\n* Participating (or intends to participate) in another drug or device clinical trial that may influence the data that will be collected for this study.",{"count":214,"type":22},[166],"Study to evaluate the effectiveness of time variant pulse (TVP)-SCS in patients with chronic pain using commercially approved Boston Scientific SCS Systems per local Instructions for use (IFU).\n\nIn addition, to compile real-world clinical outcomes in subjects with chronic, intractable low back and\u002For leg pain.",[28,536,29,537,538,539],"Intractable Pain","Chronic Low-back Pain","Chronic Leg Pain","Leg Pain",[191],{"date":542,"type":34},"2026-08-11",{"date":544,"type":34},"2025-11-07",{"date":546,"type":22},"2029-05",{"name":548,"class":41},"Boston Scientific Corporation",7,{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":554,"acronym":555,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":557,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":559,"conditions":560,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":561,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":567},"100174888","patient-retrospective-outcomes-pro-100174888","NCT01550575","Patient Retrospective Outcomes (PRO)","PRO","Key Inclusion Criteria:\n\n* Previously treated with or eligible for use with Boston Scientific Systems\n* 18 years of age or older at the start of Baseline",{"count":558,"type":22},15000,"This study will evaluate de-identified (anonymous) data in subject medical charts to review the clinical outcomes of various treatment approaches in the treatment of chronic pain.",[28],{"date":542,"type":34},{"date":563,"type":34},"2012-04-03",{"date":565,"type":22},"2030-12",{"name":548,"class":41},144,{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":575,"enrollmentInfo":576,"targetDuration":4,"studyType":23,"phases":578,"briefSummary":579,"conditions":580,"keywords":582,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":590,"locationsCount":132},"100405247","pain-and-major-depressive-disorder-100405247","NCT04556890","Pain and Major Depressive Disorder","Multi-target Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment for Major Depressive Disorder (MDD) and Comorbid Pain","Inclusion Criteria:\n\n* All Subjects must be between 18-75 years of age\n* Language: Participants must speak English fluently, as demonstrated by verbal skills sufficient to answer questions at a level that assures adequate understanding of the study\n* Must have confirmed diagnosis of moderate Major Depressive Disorder (single or recurrent episode), minimum score of 17 on the 17-item Hamilton Rating Scale for Depression (HAM-D17). No minimal MDD duration necessary for study participation\n* Failure to respond to a minimum of 2 trials of antidepressant medication\n* Failure to respond from at least two different agent classes\n* Accompanied by at least two evidence-based augmentation therapies (Benzodiazepines do not count)\n* Must have a trial of psychotherapy known to be effective in the treatment of MDD of an adequate frequency and duration\\*\n* Must have a confirmed FM or ME\u002FCFS diagnoses and moderate pain complaints, minimum score of 15 on the McGill Pain Questionnaire.\n* Pain chronicity for at least 3 months prior to study enrollment.\n* Subjects are willing and able to adhere to the treatment schedule and required study visits.\n\nExclusion Criteria:\n\n* Are mentally or legally incapacitated, unable to give informed consent.\n* Are pregnant.\n* Have an active suicidal intent or plan.\n* Have had prior Transcranial Magnetic Stimulation treatment.\n* Have an infection or poor skin condition over the scalp where the device will be positioned.\n* Have increased risk of seizure because of family history, stroke, or currently use medications that lead to increased risk for seizure.\n* Psychotic depression or other acute or chronic psychotic symptoms or disorders (such as schizophrenia, schizophreniform or schizoaffective disorder) in the current depressive episode.\n* Neurological conditions that include epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, having a history of repetitive or severe head trauma, or with primary or secondary tumors in the central nervous system.\n* Presence of an implanted metallic and magnetic-sensitive medical device present in the body scan, including but not limited to a cochlear implant, infusion pump, implanted cardioverter defibrillator, pacemaker, vagus nerve stimulator, aneurysm clip, metal prosthesis, or metal aneurysm clips or coils, staples, or stents. (Note: Dental amalgam fillings are not affected by the magnetic field and are acceptable for use with transcranial magnetic stimulation and MRI)","75 Years",{"count":577,"type":22},54,[166],"This study will examine the effects of brain stimulation on pain symptoms associated with Major depressive disorder. This study will enroll 54 Subjects. Study subjects will be asked to complete surveys about their mood and well-being, 2 blood draws, 2 MRIs, 3 electroencephalograms, and receive 30 treatments of blinded transcranial magnetic stimulation. There is no control group as all subjects will receive some form of active treatment. Subjects are required to participate in 30-33 study visits and volunteer 40 hours of their time. Compensation for this study is $150 for completing all study activities.",[581,28],"Major Depressive Disorder",[583,584,28],"TMS","MDD","2026-08-07",{"date":542,"type":34},{"date":588,"type":34},"2023-03-01",{"date":251,"type":22},{"name":591,"class":101},"University of California, Los Angeles",{"id":593,"slug":594,"hasResults":12,"nctId":595,"briefTitle":596,"officialTitle":596,"acronym":597,"eligibilityCriteria":598,"healthyVolunteers":12,"sex":18,"minAge":599,"maxAge":260,"enrollmentInfo":600,"targetDuration":4,"studyType":23,"phases":602,"briefSummary":604,"conditions":605,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":613,"locationsCount":132},"100651471","phase-4-personalized-analgesia-through-central-nervous-system-engagement-to-unlock-performance-100651471","NCT07759336","Personalized Analgesia Through Central Nervous System Engagement to Unlock Performance","PACE-UP","Inclusion Criteria:\n\n* Knee pain for greater than 6 months.\n* Moderate-to-severe knee pain (\\>3\u002F10) due to osteoarthritis, as defined by American College of Rheumatology and EULAR diagnostic criteria (Zhang 2010, Altman 1986) on \\>50% of days in the past month.\n* KL grade 2-4 (Kellgren and Lawrence 1957) indicating significant degenerative changes on knee X-ray. This will be determined on evaluation of weight-bearing clinical X-rays on review of medical records. In the infrequent situation that the patient does not have an X-ray on review of their medical records, then the patient will obtain weight-bearing knee X-rays as part of the Screening Visit.\n* Age: 45-80 years old\n* Gender: Males and females will be recruited.\n* Language: only English-speaking subjects will be included.\n\nExclusion Criteria:\n\n* Inflammatory arthritis (e.g. rheumatoid arthritis).\n* More intense pain due to another chronic pain syndrome (e.g. fibromyalgia, hip osteoarthritis)\n* Significant pain or weakness in the lower extremities due to a neurological condition (e.g. lumbar radiculopathy, paresis due to stroke)\n* New, ongoing acute pain\n* Recent use of duloxetine defined as any use within the last 3 months\n* Current use of antidepressants or tramadol\n* Current routine use of more than 30 mg oral morphine equivalents per day (use of \\\u003C=30 mg OME does not exclude the participant).\n* New treatment that may help knee osteoarthritis (including medication, exercise, behavioral, or complementary and integrative treatments) started in the last month. Stable use of treatments for greater than 1 month does not exclude the participant.\n* Unwillingness to maintain current knee osteoarthritis treatments for the duration of the study. This means that eligible participants must plan for the following: medications and dietary supplements should not change substantially in frequency or dose; behavioral therapy, exercise therapy, and complementary and integrative therapies should be consistent; and there should be no interventional treatments planned for lower extremity musculoskeletal conditions (e.g. joint steroid injections, knee radiofrequency ablation, knee replacement surgery).\n* Recent knee intra-articular injection of steroid or other agent (greater than 1 month does not exclude the participant)\n* Recent knee radiofrequency ablation (greater than 3 months does not exclude the participant)\n* Recent knee arthroscopic surgery (greater than 3 months does not exclude the participant)\n* History of knee replacement or open knee surgery on the index knee, defined as the more painful knee on average over the last month.\n* Inability to walk or climb stairs without significant assistance (e.g. a one-person assist, use a wheelchair; use of a cane does not exclude the participant).\n* Inability to participate in study procedures (e.g. cognitive impairment limiting ability to understand directions, inability to understand and read English)\n* Uncontrolled or unstable medical disorder preventing participation in study procedures\n* History of brain surgery\n* Tattoos on sensory testing sites\n* Pregnancy\n* History of severe renal impairment defined by GFR \\\u003C 30 ml\u002Fmin or, if renal function testing is not available on EMR review, patient-reported history of acute or chronic kidney disease of any severity\n* History of chronic liver disease or cirrhosis\n* History of angle-closure glaucoma","45 Years",{"count":601,"type":22},85,[603],"PHASE4","The goal of this clinical trial is to examine the effects of duloxetine on walking ability and physical activity in patients with knee osteoarthritis. Researchers will compare duloxetine to a placebo (a look-alike substance that contains no drug) to see if duloxetine works to improve walking ability in patients with knee osteoarthritis. At study visits, participants will complete surveys, perform physical function tasks, undergo non-invasive brain imaging, and undergo sensory testing.",[606,28,607],"Knee Osteoarthritis (Knee OA)","Chronic Knee Pain","2026-08-06",{"date":36,"type":34},{"date":611,"type":22},"2026-08",{"date":291,"type":22},{"name":614,"class":101},"Benedict Alter",{"id":616,"slug":617,"hasResults":12,"nctId":618,"briefTitle":619,"officialTitle":620,"acronym":621,"eligibilityCriteria":622,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":623,"targetDuration":4,"studyType":23,"phases":625,"briefSummary":626,"conditions":627,"keywords":628,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":632,"startDateStruct":633,"completionDateStruct":635,"leadSponsor":637,"locationsCount":132},"100650906","pop-singer-randomized-clinical-trial-100650906","NCT07756541","POP SINGER Randomized Clinical Trial","Pain Management Optimized Through Patient-centered Multi-Session Group Music Therapy Within INteGrative sharEd progRamming: A Feasibility Randomized Controlled Trial","POP SINGER RCT","Inclusion Criteria:\n\n1. Adults aged 18 and older\n2. Reporting pain on most days per month for a duration of ≥3 months\n3. Independently ambulatory (i.e., able to walk 10 feet without a cane or walker)\n4. Willing to participate in the full scope of the program\n5. Access to internet, active email address, \\& laptop, tablet, and\u002For PC with videoconferencing capabilities\n6. Have reliable access to a mobile device with an active data plan at home and is comfortable accessing the internet and their email with this device\n7. Able to read and understand English\n\nExclusion Criteria:\n\n1. Significant hearing and\u002For visual impairment\n2. Have had a major surgery (e.g., spine surgery, joint replacement) within the past 6 months\n3. Have a planned surgery within the next 6 months at the time of enrollment\n4. Unable to independently provide consent (i.e., no proxy consent)\n5. Active suicidal ideation\n6. Severe psychological comorbidity (e.g., psychosis, schizophrenia) that would prevent patient from engaging fully in intervention\n7. Receiving active cancer treatment.\n8. Diagnosed with medical condition likely to be terminal within 24 weeks\n9. Either (a) active substance abuse of cocaine, heroin, cannabis, or alcohol or (b) unmanaged opioid use disorder diagnosis present within the EHR in the last 6 months\n10. Currently receiving music therapy from a professional music therapist\n11. Currently engaged in regular weekly yoga practice",{"count":624,"type":22},130,[166],"Conduct a feasibility randomized controlled trial (N = 130, 65 per group) comparing the POPSINGER music therapy (MT) intervention to yoga.",[28],[629,630,631],"Chronic pain","Music Therapy","Yoga",{"date":496,"type":34},{"date":634,"type":34},"2026-07-29",{"date":636,"type":22},"2028-08-01",{"name":638,"class":101},"University Hospitals Cleveland Medical Center"]